MX391847B - Anticuerpos anti-flt-1 para tratar displasia broncopulmonar. - Google Patents
Anticuerpos anti-flt-1 para tratar displasia broncopulmonar.Info
- Publication number
- MX391847B MX391847B MX2017012827A MX2017012827A MX391847B MX 391847 B MX391847 B MX 391847B MX 2017012827 A MX2017012827 A MX 2017012827A MX 2017012827 A MX2017012827 A MX 2017012827A MX 391847 B MX391847 B MX 391847B
- Authority
- MX
- Mexico
- Prior art keywords
- flt
- bpd
- bronchopulmonary dysplasia
- antibodies
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144241P | 2015-04-07 | 2015-04-07 | |
| PCT/US2016/026420 WO2016164567A1 (en) | 2015-04-07 | 2016-04-07 | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017012827A MX2017012827A (es) | 2018-02-23 |
| MX391847B true MX391847B (es) | 2025-03-21 |
Family
ID=55969453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012827A MX391847B (es) | 2015-04-07 | 2016-04-07 | Anticuerpos anti-flt-1 para tratar displasia broncopulmonar. |
| MX2022004164A MX2022004164A (es) | 2015-04-07 | 2017-10-05 | Anticuerpos anti-flt-1 para tratar displasia broncopulmonar. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004164A MX2022004164A (es) | 2015-04-07 | 2017-10-05 | Anticuerpos anti-flt-1 para tratar displasia broncopulmonar. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10738123B2 (enExample) |
| EP (1) | EP3280737B1 (enExample) |
| JP (1) | JP6797826B2 (enExample) |
| CN (1) | CN107690335A (enExample) |
| AU (1) | AU2016246730B2 (enExample) |
| BR (1) | BR112017021413A2 (enExample) |
| HK (1) | HK1249908A1 (enExample) |
| MA (1) | MA41908A (enExample) |
| MX (2) | MX391847B (enExample) |
| WO (1) | WO2016164567A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX385370B (es) * | 2016-03-31 | 2025-03-18 | Immutrix Therapeutics Inc | Metodo para el tratamiento extracorporeo de preeclampsia y trastornos relacionados. |
| CN113260628A (zh) * | 2018-06-22 | 2021-08-13 | 夏尔人类遗传性治疗公司 | 治疗支气管肺发育不良的抗flt-1抗体 |
| EP3936054A1 (en) * | 2020-07-08 | 2022-01-12 | Assistance Publique - Hôpitaux de Paris | Method of prognosis of bronchopulmonary dysplasia in premature infants |
| AU2022331414A1 (en) * | 2021-08-16 | 2024-04-04 | Janssen Biotech, Inc. | Anti-vegfr1 antibodies and their uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7335362B2 (en) * | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
| US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| JP5650876B2 (ja) * | 2002-07-19 | 2015-01-07 | ベス・イスラエル・ディーコニス・メディカル・センター | 子癇前症または子癇の診断方法および治療方法 |
| EP2377555A3 (en) | 2004-11-18 | 2011-11-23 | Imclone LLC | Antibodies against vascular endothelial growth factor receptor-1 |
| US20060153835A1 (en) | 2005-01-12 | 2006-07-13 | Smith Henry J | Treatment of pre-eclampsia in pregnant women using targeted apheresis |
| US8349325B2 (en) | 2008-12-23 | 2013-01-08 | Abbott Laboratories | Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making |
| CA2826563C (en) * | 2011-02-07 | 2020-10-20 | Paul Kussie | Methods and systems for treating eclampsia and pre-eclampsia |
| CN104955843B (zh) | 2013-01-28 | 2019-08-13 | 夏尔人类遗传性治疗公司 | 治疗杜兴氏肌营养不良的抗flt-1抗体 |
| TW201517916A (zh) | 2013-03-15 | 2015-05-16 | Lilly Co Eli | Ｖｅｇｆｒ１抗體之治療用途 |
-
2016
- 2016-04-07 US US15/564,969 patent/US10738123B2/en active Active
- 2016-04-07 JP JP2017552910A patent/JP6797826B2/ja active Active
- 2016-04-07 MA MA041908A patent/MA41908A/fr unknown
- 2016-04-07 CN CN201680032805.1A patent/CN107690335A/zh active Pending
- 2016-04-07 MX MX2017012827A patent/MX391847B/es unknown
- 2016-04-07 BR BR112017021413A patent/BR112017021413A2/pt not_active Application Discontinuation
- 2016-04-07 EP EP16722725.5A patent/EP3280737B1/en active Active
- 2016-04-07 WO PCT/US2016/026420 patent/WO2016164567A1/en not_active Ceased
- 2016-04-07 AU AU2016246730A patent/AU2016246730B2/en active Active
- 2016-04-07 HK HK18109294.4A patent/HK1249908A1/zh unknown
-
2017
- 2017-10-05 MX MX2022004164A patent/MX2022004164A/es unknown
-
2019
- 2019-12-05 US US16/704,861 patent/US20200362041A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018515442A (ja) | 2018-06-14 |
| US10738123B2 (en) | 2020-08-11 |
| US20180072805A1 (en) | 2018-03-15 |
| EP3280737B1 (en) | 2022-03-09 |
| WO2016164567A1 (en) | 2016-10-13 |
| AU2016246730A1 (en) | 2017-10-26 |
| AU2016246730B2 (en) | 2021-11-11 |
| HK1249908A1 (zh) | 2018-11-16 |
| EP3280737A1 (en) | 2018-02-14 |
| US20200362041A1 (en) | 2020-11-19 |
| MX2022004164A (es) | 2022-05-02 |
| BR112017021413A2 (pt) | 2018-07-03 |
| MX2017012827A (es) | 2018-02-23 |
| MA41908A (fr) | 2021-03-31 |
| CN107690335A (zh) | 2018-02-13 |
| JP6797826B2 (ja) | 2020-12-09 |
| CA2982815A1 (en) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202500956B (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| PH12021550023A1 (en) | Humanized anti-tau antibodies | |
| MX360153B (es) | Anticuerpos anti-flt-1 para tratar la distrofia muscular de duchenne. | |
| MX382549B (es) | Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1. | |
| BR112018012929A2 (pt) | anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda | |
| MX2022008255A (es) | Anticuerpo anti-il-13 para usarse en el tratamiento de esofagitis eosinofilica. | |
| EA201590719A1 (ru) | Фоллистатин в лечении мышечной дистрофии дюшенна | |
| EA201890578A1 (ru) | Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли | |
| MX2017001959A (es) | Anticuerpos especificos para mmp9. | |
| SA518390944B1 (ar) | أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها | |
| MX2022004164A (es) | Anticuerpos anti-flt-1 para tratar displasia broncopulmonar. | |
| MX2018010470A (es) | Proteinas de fusion folistatina-fc recombinantes y su uso en el tratamiento de la distrofia muscular de duchenne. | |
| MX2019013523A (es) | Proteínas de fusión de folistatina-fc recombinante y uso en el tratamiento de la distrofia muscular de duchenne. | |
| MX2022015677A (es) | Metodos para tratar la alergia usando anticuerpos anti-bet v 1. | |
| PH12019500342A1 (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
| MX2017012828A (es) | Anticuerpos anti-flt-1 para el tratamiento de distrofia muscular de duchenne. | |
| JOP20210279A1 (ar) | طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي | |
| MX2017012831A (es) | Anticuerpos anti receptor del factor de crecimiento endotelial vascular 1 (flt-1) en el tratamiento de displasia broncopulmonar. | |
| PH12022551401A1 (en) | Antibodies for the treatment of chronic graft versus host disease | |
| PH12018501674A1 (en) | Anti-citrullinated hla polypeptide antibodies and uses thereof | |
| ZA202106551B (en) | Anti-bag2 antibody and methods of treating cancer | |
| EA202092640A1 (ru) | Способы и композиции для лечения хронической крапивницы | |
| EA202090583A1 (ru) | Композиции на основе антител против a33 и способы их применения в радиоиммунотерапии | |
| MX2021000268A (es) | Anticuerpos contra especies de campylobacter. |